There has been much talk recently about the challenge of retaining talent in life sciences, particularly in relation to safety and regulatory disciplines, where younger professionals’ ambitions for a broad base of experience are jarring with companies’ needs to hold onto expertise they have invested in.

Local affiliates are arguably just as in need of outsourcing support as primary pharma locations. But drawing on such services should be frictionless, and involve close coordination with the vision and goals of HQ. Anna Lukyanova COO of Arriello, explores where biotech and pharma firms can go awry in their international service use, and offers tips on how to ease the transition for all.

Relieving local affiliates of heavy regulatory and/or pharmacovigilance workloads via a coordinated approach to outsourcing should be perfectly viable, but a frictionless global plan requires close coordination with HQ-level activities. Anna Lukyanova, COO of Arriello, offers advice on how to achieve a smooth transition...

Advanced digital tools are certain to play a pivotal role in the redesign of labour-intensive regulatory processes, but there is a danger that AI's potential contribution is being over-hyped to life sciences firms. Arriello's CEO Alan White warns that the key to ROI is in the application...

Never previously at the forefront of technology innovation, the life sciences industry now accepts that it needs to transform its agility, responsiveness and cost-efficiency, and that advanced digital tools are likely to form an important part of that strategy. Advanced digital tools are certain to play a pivotal role in the redesign of labour-intensive regulatory processes, but there is a danger that AI's potential contribution is being over-hyped. Arriello's CEO Alan White warns that the key to ROI is in the application...

Automation technology will play a key role in transforming labour-intensive regulatory processes in life sciences, but is AI being oversold by business process delivery partners? Alan White, CEO of Arriello, warns that focused application is essential to delivering results.

Soaring merger & acquisition activity in life sciences threatens competition and reduces customer options, both to patients and to pharma and biotech firms seeking help with growing pharmacovigilance and regulatory filing requirements. Alan White of Arriello explains why it has never been more important to choose wisely.